SCHEMBL1059338

SCHEMBL1059338

CCCCCCCC/C=C\C/C=C\CCCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 1.00
PPARD Q03181 6/20 1.00
PPARA Q07869 6/20 1.00
ALDH1A1 P00352 5/20 1.00
F7 P08709 5/20 1.00
F3 P13726 5/20 1.00
FABP4 P15090 4/20 1.00
HSD17B10 Q99714 4/20 1.00
FFAR1 O14842 3/20 1.00
PTGS1 P23219 3/20 1.00
LMNA P02545 3/20 1.00
CYP19A1 P11511 3/20 1.00
ALOX15 P16050 3/20 1.00
NR4A2 P43354 3/20 1.00
KDM4E B2RXH2 2/20 1.00
CYP3A4 P08684 2/20 1.00
HPGD P15428 2/20 1.00
AKR1C3 P42330 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
DUSP3 P51452 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16685715 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
SCHEMBL15880317 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
Linoleic Acid SCHEMBL20856202 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
SCHEMBL22498259 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
SCHEMBL22498256 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
Arachidic Acid SCHEMBL20528087 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
Linoleic Acid SCHEMBL25294178 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
SCHEMBL22498258 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
Dihomo-Gamma-Linolenic Acid SCHEMBL20656585 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
SCHEMBL21411004 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426625-B2 Bis-platinum complexes with antitumor activity CELL THERAPEUTICS, INC. (US) 2013-04-23 US claimed
US-20100292322-A1 Bis-Platinum Complexes With Antitumor Activity CELL THERAPEUTICS, INC. 2010-11-18 US claimed
EP-1968991-A1 BIS-PLATINUM COMPLEXES WITH ANTITUMOR ACTIVITY Sede Secondaria Della Cell Therapeutics, Inc. (IT) 2008-09-17 EP claimed
WO-2007071415-A1 BIS-PLATINUM COMPLEXES WITH ANTITUMOR ACTIVITY CELL THERAPEUTICS, INC. - SEDE SECONDARIA (IT) 2007-06-28 WO claimed
US-20260139250-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS THE CHILDRENS MEDICAL CENTER CORP (US) 2026-05-21 US disclosed
US-12590320-B2 Cellular models of and therapies for ocular diseases REFLECTION BIOTECHNOLOGIES LIMITED (HK) 2026-03-31 US disclosed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US disclosed
EP-4583720-A1 COMPOSITIONS AND METHODS FOR PRODUCING MEAT-LIKE AROMAS Nourish Ingredients Pty Ltd (AU) 2025-07-16 EP disclosed
EP-4583721-A1 COMPOSITIONS AND METHODS FOR PRODUCING MEAT-LIKE AROMAS Nourish Ingredients Pty Ltd (AU) 2025-07-16 EP disclosed
EP-4583719-A1 COMPOSITIONS AND METHODS FOR PRODUCING AROMAS Nourish Ingredients Pty Ltd (AU) 2025-07-16 EP disclosed
EP-4551702-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS The Children's Medical Center Corporation (US) 2025-05-14 EP disclosed
WO-2025085964-A1 SHORT CHAIN LIPIDS Nourish Ingredients Pty Ltd (AU) 2025-05-01 WO disclosed
US-20100330160-A1 Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 SANOFI PASTEUR (FR) 2010-12-30 US disclosed
US-20100292322-A1 Bis-Platinum Complexes With Antitumor Activity CELL THERAPEUTICS, INC. 2010-11-18 US disclosed
US-20100291192-A1 Detoxification method for lipopolysaccharide (LPS) or lipid A of gram-negative bacteria SANOFI PASTEUR (FR) 2010-11-18 US disclosed
EP-1968991-A1 BIS-PLATINUM COMPLEXES WITH ANTITUMOR ACTIVITY Sede Secondaria Della Cell Therapeutics, Inc. (IT) 2008-09-17 EP disclosed
EP-1484445-B1 Use of carboxylic perfluoropolyethers for the oleo-repellent paper sizing SOLVAY SOLEXIS SPA (IT) 2007-07-11 EP disclosed
WO-2007071415-A1 BIS-PLATINUM COMPLEXES WITH ANTITUMOR ACTIVITY CELL THERAPEUTICS, INC. - SEDE SECONDARIA (IT) 2007-06-28 WO disclosed
EP-1489124-A1 (Per)fluoropolyether carboxylic acids and use thereof for the oleo-repellent paper sizing Solvay Solexis S.p.A. (IT) 2004-12-22 EP disclosed
EP-1484445-A1 Use of carboxylic perfluoropolyethers for the oleo-repellent paper sizing Solvay Solexis S.p.A. (IT) 2004-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292322-A1 Bis-Platinum Complexes With Antitumor Activity IDH3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1 PPARG 1538/4885PPARD 1665/4885PPARA 1311/4885
US-20260139250-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS TRDMT1, METTL16, TRMT1 PPARG 3490/4885PPARD 4218/4885PPARA 3987/4885
US-20100330160-A1 Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 PHOSPHO1, FUT6, MAGT1 PPARG 4163/4885PPARD 4405/4885PPARA 3152/4885
US-12590320-B2 Cellular models of and therapies for ocular diseases ALDH1A2, NR2E3, RBP4 PPARG 1904/4885PPARD 1504/4885PPARA 3583/4885
US-20100291192-A1 Detoxification method for lipopolysaccharide (LPS) or lipid A of gram-negative bacteria LIPA, MGLL, LIPC PPARG 158/4885PPARD 617/4885PPARA 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.